Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple…
<!-- Name:DistributionId Value:8829281 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:True -->
<!-- Name:IcbCode Value:4577 -->…
Browsing Tag
analyses
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic…
<!-- Name:DistributionId Value:8823381 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
How technoeconomic analyses pave the way to a low-carbon future
Credit: Shutterstock
Levels of planet-warming carbon dioxide in the air continue to rise. Cutting emissions by moving away from fossil fuels…
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in…
<!-- Name:DistributionId Value:8799088 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual…
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.…
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO…
<!-- Name:DistributionId Value:8754743 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:9530 -->…
Current microbiome analyses may falsely detect species that are not actually present: Study of…
Common approaches to analyze DNA from a community of microbes, called a microbiome, can yield erroneous results, in large part due to the incomplete databases used to identify microbial DNA sequences. A team led by Aiese Cigliano of…
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced…
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across…
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 (“Ensifentrine as a Novel…
College student ‘Fear of Missing Out’ (FoMO) associated with illicit behavior: Two…
The fear of missing out (FoMO) on rewarding and fun experiences is something that most people feel at some point in life. Among college students, the degree to which someone experiences FoMO is associated with their risk of participating in…